优恺泽生物医药

UKZ Biopharma is an innovative biotechnology company headquartered in Suzhou, China, dedicated to the discovery and development of targeted protein degradation (TPD) medicines. The company utilizes its proprietary technology platform to develop Proteolysis Targeting Chimeras (PROTACs) and molecular glues that harness the body's natural protein disposal system to eliminate disease-causing proteins. UKZ Biopharma primarily focuses on oncology, aiming to provide new treatment options for patients with undruggable targets or those who have developed resistance to traditional small molecule inhibitors. Led by a team of experts in medicinal chemistry and drug discovery, the firm is advancing a pipeline of early-stage candidates toward clinical development. The company is supported by prominent regional investors and is situated within the Suzhou Industrial Park biotech ecosystem.